AbbVie acquired Apogee to significantly strengthen and future-proof its industry-leading immunology franchise. With former top-selling drugs facing intense biosimilar market competition and future patent expirations threatening revenue streams, AbbVie targeted Apogee's highly differentiated pipeline of advanced antibody therapies—such as zumilokibart—to secure new long-term growth drivers in inflammatory and immunological disease treatments.